{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-22-000011","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.076700+00:00","generated_at":"2026-06-25T18:14:50.773886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroPace Q1 revenue $11.4M, net loss widens to $11.5M; guides FY2022 revenue $45-48M","bullets":["Total revenue $11.4M (+2% YoY); initial implant rev $8.8M (+9%); replacement rev $2.6M (-16%).","Net loss widened to $11.5M from $8.8M; operating expenses $18.0M vs $12.4M.","Gross margin 73% vs 76% due to higher costs and COVID disruptions; cash $103.2M.","FY2022 guidance: revenue $45-48M, initial implants $39-42M, opex $74-76M.","On track to enroll first patients in NAUTILUS trial for generalized epilepsy expansion mid-2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-22-000011","json":"https://secwatch.observer/filing/0001528287-22-000011.json","markdown":"https://secwatch.observer/filing/0001528287-22-000011.md","text":"https://secwatch.observer/filing/0001528287-22-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000011/0001528287-22-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000011/npce-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:14:50.773886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}